- Home
- RVPHW vs GLP Comparison
RVPHW vs GLP Comparison
Compare RVPHW & GLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- GLP
- Stock Information
- Founded
- RVPHW 2018
- GLP 2005
- Country
- RVPHW United States
- GLP United States
- Employees
- RVPHW 15
- GLP N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- GLP Oil Refining/Marketing
- Sector
- RVPHW Health Care
- GLP Energy
- Exchange
- RVPHW Nasdaq
- GLP Nasdaq
- Market Cap
- RVPHW N/A
- GLP N/A
- IPO Year
- RVPHW N/A
- GLP 2005
- Fundamental
- Price
- RVPHW $0.03
- GLP $55.55
- Analyst Decision
- RVPHW
- GLP Hold
- Analyst Count
- RVPHW 0
- GLP 1
- Target Price
- RVPHW N/A
- GLP $56.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- GLP 65.3K
- Earning Date
- RVPHW 03-14-2025
- GLP 05-07-2025
- Dividend Yield
- RVPHW N/A
- GLP 5.21%
- EPS Growth
- RVPHW N/A
- GLP N/A
- EPS
- RVPHW N/A
- GLP 2.41
- Revenue
- RVPHW N/A
- GLP $17,163,565,999.00
- Revenue This Year
- RVPHW N/A
- GLP $44.97
- Revenue Next Year
- RVPHW N/A
- GLP $8.73
- P/E Ratio
- RVPHW N/A
- GLP $23.09
- Revenue Growth
- RVPHW N/A
- GLP 4.07
- 52 Week Low
- RVPHW $0.13
- GLP $37.00
- 52 Week High
- RVPHW $0.15
- GLP $60.00
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- GLP 55.18
- Support Level
- RVPHW N/A
- GLP $53.19
- Resistance Level
- RVPHW N/A
- GLP $54.48
- Average True Range (ATR)
- RVPHW 0.00
- GLP 1.83
- MACD
- RVPHW 0.00
- GLP 0.13
- Stochastic Oscillator
- RVPHW 0.00
- GLP 78.12
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.